Intramyocardial Stem Cell Injection in Patients With Ischemic Cardiomyopathy Functional Recovery and Reverse Remodeling

Interdisciplinary Stem Cell Institute, Department of Medicine, University of Miami Miller School of Medicine, 1501 NW 10th Ave., Miami, FL 33136, USA.
Circulation Research (Impact Factor: 11.09). 03/2011; 108(7):792-6. DOI: 10.1161/CIRCRESAHA.111.242610
Source: PubMed

ABSTRACT Transcatheter, intramyocardial injections of bone marrow-derived cell therapy produces reverse remodeling in large animal models of ischemic cardiomyopathy.
We used cardiac MRI (CMR) in patients with left ventricular (LV) dysfunction related to remote myocardial infarction (MI) to test the hypothesis that bone marrow progenitor cell injection causes functional recovery of scarred myocardium and reverse remodeling.
Eight patients (aged 57.2±13.3 years) received transendocardial, intramyocardial injection of autologous bone marrow progenitor cells (mononuclear or mesenchymal stem cells) in LV scar and border zone. All patients tolerated the procedure with no serious adverse events. CMR at 1 year demonstrated a decrease in end diastolic volume (208.7±20.4 versus 167.4±7.32 mL; P=0.03), a trend toward decreased end systolic volume (142.4±16.5 versus 107.6±7.4 mL; P=0.06), decreased infarct size (P<0.05), and improved regional LV function by peak Eulerian circumferential strain in the treated infarct zone (-8.1±1.0 versus -11.4±1.3; P=0.04). Improvements in regional function were evident at 3 months, whereas the changes in chamber dimensions were not significant until 6 months. Improved regional function in the infarct zone strongly correlated with reduction of end diastolic volume (r(2)=0.69, P=0.04) and end systolic volume (r(2)=0.83, P=0.01).
These data suggest that transcatheter, intramyocardial injections of autologous bone marrow progenitor cells improve regional contractility of a chronic myocardial scar, and these changes predict subsequent reverse remodeling. The findings support the potential clinical benefits of this new treatment strategy and ongoing randomized clinical trials.


Available from: Alan Heldman, Aug 04, 2014
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: To investigate the efficacy and feasibility of percutaneous intramyocardial injection of bone marrow mesenchymal stem cells (MSC) and autologous bone marrow-derived mononuclear cells (BMMNC) on cardiac functional improvement in porcine myocardial infarcted hearts. Acute myocardial infarction (AMI) was induced in 22 minipigs by temporary balloon occlusion of the left anterior descending coronary artery for 60min.Two weeks post AMI, BMMNC (n = 7, 245 ± 98×10(6)), MSC (n = 8, 56 ± 17×10(6)), or phosphate buffered saline (PBS; n = 7) were injected intramyocardially. Cardiac function and myocardial perfusion were analyzed by echocardiography and gated single-photon emission computed tomography/computed tomography (SPECT/CT) at 1 week before AMI and 2 and 10 weeks after AMI. Cell engraftment, proliferation, vascular density, and cardiac fibrosis were evaluated by histology analysis. In all groups, the echocardiography revealed no significant change in the left ventricular ejection fraction (LVEF), left ventricular end-systolic volume (LVESV), or left ventricular end-diastolic volume (LVEDV) at 10 weeks after AMI compared with those at 2 weeks after AMI. However, the wall motion score index (WMSI) and left ventricular systolic wall thickening (WT%) were significantly improved at 10 weeks compared with those at 2 weeks after AMI in the MSC group (WMSI 1.55 ± 0.06 vs. 1.87 ± 0.10, WT 33.4 ± 2.3% vs.24.8 ± 2.7%,p < 0.05) but not in the BMMNC group. In addition, myocardial perfusion quantified by SPECT/CT was improved in both the MSC and BMMNC groups, whereas the MSC group showed a superior improvement in vascular density and collagen volume fraction (p < 0.05). This preclinically relevant study suggests that when delivered by percutaneous (transcatheter) intramyocardial injection, MSC might be more effective than BMMNC to improve ischemia and reperfusion after AMI.
    Theranostics 01/2015; 5(2):196-205. DOI:10.7150/thno.7976 · 7.83 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Over the last years, stem cell therapy has emerged as an inspiring alternative to restore cardiac function after myocardial infarction. A large body of evidence has been obtained in this field but there is no conclusive data on the efficacy of these treatments. Preclinical studies and early reports in humans have been encouraging and have fostered a rapid clinical translation, but positive results have not been uniformly observed and when present, they have been modest. Several types of stem cells, manufacturing methods and delivery routes have been tested in different clinical settings but direct comparison between them is challenging and hinders further research. Despite enormous achievements, major barriers have been found and many fundamental issues remain to be resolved. A better knowledge of the molecular mechanisms implicated in cardiac development and myocardial regeneration is critically needed to overcome some of these hurdles. Genetic and pharmacological priming together with the discovery of new sources of cells have led to a "second generation" of cell products that holds an encouraging promise in cardiovascular regenerative medicine. In this report, we review recent advances in this field focusing on the new types of stem cells that are currently being tested in human beings and on the novel strategies employed to boost cell performance in order to improve cardiac function and outcomes after myocardial infarction.
    03/2015; 7(2):352-367. DOI:10.4252/wjsc.v7.i2.352
  • [Show abstract] [Hide abstract]
    ABSTRACT: The migration of mesenchymal stem cell (MSCs) plays a key role in tumor-targeted delivery vehicles and tumor-related stroma formation. However, there has been no report to date on the distribution of cell surface molecules during the VEGF-induced migration of MSCs, which may be important in elucidating the molecular mechanism behind this phenomenon. Here, we used near-field scanning optical microscopy (NSOM) combined with fluorescent quantum dot (QD)-based nano-technology to capture the functional relationship between CD44 and CD29 adhesion molecules on MSCs and the effect of their spatial rearrangements. Before VEGF-induced migration of MSCs, both CD44 and CD29 formed 200 - 220nm nano-domains with little co-localization between the two types of domains. Surprisingly, the size of the CD44 nano-domain rapidly increased in size to 295nm and formed obviously larger aggregates following MSC treatment by VEGF for 10min, while the area of co-localization increased to 0.327μm(2). Compared with CD44, the CD29 activation is obvious later than the CD44 for the fact that CD29 rapidly formed the larger aggregation as long as VEGF treatment for 30min. Then, the co-localization area increased to 0.917μm(2). The CD44 and CD29 nano-domain further aggregated into larger nano-domain or even formed micro-domain on the membrane of activated MSCs. The aggregation and co-localization of these molecules could favor of FAK formation and cytoskeleton rearrangement. This was supported by the result that the expression level of FAK was increased with the addition of VEGF. And, the actin filaments developed a parallelized pattern which was strongly related to the VEGF gradient. All of the changes induced by VEGF contributed MSC migration. Taken together, our data of NSOM-based dual color fluorescent imaging demonstrated for the first time that VEGF-induced migration of MSCs was involved in engagement of CD44 and CD29 through coreceptor CD44 for VEGFR-2. Copyright © 2014. Published by Elsevier B.V.
    Biochimica et Biophysica Acta (BBA) - Biomembranes 12/2014; 1848(3). DOI:10.1016/j.bbamem.2014.12.013 · 3.43 Impact Factor